CYP2D6 and breast carcinoma: As we have previously stated, one-third of our population showed abnormal metabolism of CYP2D6, requiring a therapeutical change to an alternative hormonal therapy in order to avoid a ~2- or 3-fold increased risk of breast cancer recurrence [51].